These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1697498)

  • 1. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
    Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
    Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
    Smith PH; Bono A; Calais da Silva F; Debruyne F; Denis L; Robinson P; Sylvester R; Armitage TG
    Cancer; 1990 Sep; 66(5 Suppl):1009-16. PubMed ID: 2144203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
    Keuppens F; Denis L; Smith P; Carvalho AP; Newling D; Bond A; Sylvester R; De Pauw M; Vermeylen K; Ongena P
    Cancer; 1990 Sep; 66(5 Suppl):1045-57. PubMed ID: 2144206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
    Denis L; Smith PH; De Moura JL; Newling DW; Bono A; Keuppens F; Robinson M; Mahler C; Sylvester R; De Pauw M
    Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
    Iversen P
    Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
    Robinson MR; Denis L; Newling DW; Sylvester R; De Pauw M
    Cancer; 1990 Sep; 66(5 Suppl):1022-4. PubMed ID: 2144204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
    Iversen P; Suciu S; Sylvester R; Christensen I; Denis L
    Cancer; 1990 Sep; 66(5 Suppl):1067-73. PubMed ID: 2144208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
    Iversen P; Christensen MG; Friis E; Hornbøl P; Hvidt V; Iversen HG; Klarskov P; Krarup T; Lund F; Mogensen P
    Cancer; 1990 Sep; 66(5 Suppl):1058-66. PubMed ID: 2144207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Oneto F; Martorana G; Giuliani L; Delli Ponti U; Petracco S; Cortellini P
    Eur Urol; 1990; 18 Suppl 3():48-53. PubMed ID: 2151277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
    Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
    Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of biochemical markers in the management of disseminated prostatic cancer.
    Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
    Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
    Denis L; Robinson M; Mahler C; Smith P; Keuppens F; De Moura JL; Bono A; Newling D; Sylvester R; De Pauw M
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):951-9. PubMed ID: 2149508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
    Suciu S; Sylvester R; Iversen P; Christensen I; Denis L
    Cancer; 1990 Sep; 66(5 Suppl):1029-34. PubMed ID: 2144205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Jurincic CD; Horlbeck R; Klippel KF
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
    Leo ME; Bilhartz DL; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Apr; 145(4):802-6. PubMed ID: 1706440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
    Dennis ER; Jia X; Mezheritskiy IS; Stephenson RD; Schoder H; Fox JJ; Heller G; Scher HI; Larson SM; Morris MJ
    J Clin Oncol; 2012 Feb; 30(5):519-24. PubMed ID: 22231045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
    Emtage LA; Lewis PW; Blackledge GR
    Br J Urol; 1987 Dec; 60(6):572-7. PubMed ID: 2447997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
    Fourcade RO; Cariou G; Coloby P; Colombel P; Coulange C; Grise P; Mangin P; Soret JY; Poterre M
    Eur Urol; 1990; 18 Suppl 3():45-7. PubMed ID: 2151276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).
    Collette L; de Reijke TM; Schröder FH;
    Eur Urol; 2003 Aug; 44(2):182-9; discussion 189. PubMed ID: 12875936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.